within Pharmacolibrary.Drugs.N_NervousSystem.N06D_AntiDementiaDrugs.N06DX05_Donanemab;

model Donanemab
  extends Pharmacolibrary.Drugs.ATC.N.N06DX05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N06DX05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Donanemab is a humanized IgG1 monoclonal antibody that targets amyloid-beta plaques in the brain. It is being developed as a disease-modifying treatment for Alzheimer's disease and is currently under regulatory review, not yet fully approved for general use as of June 2024.</p><h4>Pharmacokinetics</h4><p>Population PK results in patients with early symptomatic Alzheimer’s disease; typical demographics: both sexes, older adults.</p><h4>References</h4><ol><li><p>Lowe, SL, et al., &amp; Sims, JR (2021). Donanemab (LY3002813) Phase 1b Study in Alzheimer&#x27;s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. <i>The journal of prevention of Alzheimer&#x27;s disease</i> 8(4) 414–424. DOI:<a href=&quot;https://doi.org/10.14283/jpad.2021.56&quot;>10.14283/jpad.2021.56</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34585215/&quot;>https://pubmed.ncbi.nlm.nih.gov/34585215</a></p></li><li><p>Xu, J, et al., &amp; Cui, Y (2025). Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study. <i>Clinical pharmacology in drug development</i> None –. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1533&quot;>10.1002/cpdd.1533</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40377397/&quot;>https://pubmed.ncbi.nlm.nih.gov/40377397</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Donanemab;
